Detailed Clinical Summary Patient Details * Age/Sex: 55-year-old male * Diagnosis: JAK2-positive myeloproliferative neoplasm (most consistent with Polycythemia Vera) * Duration of illness: Approximately 10 years ⸻ Initial Disease Course The patient was diagnosed with JAK2-positive Polycythemia Vera around 10 years ago and has been managed with: * Hydroxyurea (initially 500 mg once daily) * Intermittent therapeutic phlebotomy * Aspirin 150 mg once daily He remained clinically stable for several years. ⸻ Recent Clinical Progression (Last 7 Months) During the last 7 months, the patient developed persistent leukocytosis despite treatment. Laboratory Findings * WBC persistently around 22,000/µL * Hemoglobin: 14–17 g/dL * Platelet count: 5–7 lakh/µL Clinical Findings * Splenomegaly present Peripheral Smear * Normocytic normochromic RBCs * Tear-drop cells present * Neutrophilic leukocytosis * Thrombocytosis These findings raised concern for progression of long-standing Polycythemia Vera, with possible evolution toward post-polycythemia vera myelofibrosis. ⸻ Treatment Modification Because of persistent leukocytosis, the Hydroxyurea dose was increased from 500 mg/day to 1000 mg/day. ⸻ CBC Trend While receiving approximately 750 mg/day (25 May 2026) * Hemoglobin: 13.6 g/dL * WBC: 17,300/µL * Platelets: 3.66 lakh/µL * RBC: 3.99 million/µL * MCV: 104.5 fL Interpretation: * Persistent leukocytosis despite partial cytoreduction. ⸻ After approximately 4 weeks of Hydroxyurea 1000 mg/day (23 June 2026) * Hemoglobin: 12.8 g/dL * WBC: 10,000/µL * Platelets: 4.22 lakh/µL * RBC: 3.66 million/µL * MCV: 123 fL Interpretation: * Excellent hematologic response. * Leukocytosis normalized. * Platelets remained controlled. * Mild decline in hemoglobin and RBC count. * Significant macrocytosis consistent with Hydroxyurea therapy. ⸻ Latest CBC (04 July 2026) * Hemoglobin: 13.2 g/dL * WBC: 13,200/µL * Platelets: 4.50 lakh/µL * RBC: 3.10 million/µL * MCV: 123 fL Interpretation: * WBC slightly increased from previous value but remains substantially improved compared with baseline. * Platelets remain within acceptable target. * Hemoglobin has improved compared with the previous CBC. * Persistent macrocytosis is expected with Hydroxyurea. ⸻ Current Medications * Hydroxyurea 1000 mg once daily * Aspirin 150 mg once daily ⸻ Clinical Assessment The patient demonstrates: * Long-standing JAK2-positive Polycythemia Vera. * Persistent splenomegaly. * Tear-drop cells on peripheral smear. * Good hematologic response to escalation of Hydroxyurea. * No current evidence of blast transformation based on available blood counts. * No thrombocytopenia. * No severe anemia. What next need to do
polycythemia vera hydroxyurea resistance progression myelofibrosis
polycythemia vera JAK2 ruxolitinib treatment guidelines
post-polycythemia vera myelofibrosis diagnosis criteria management 2024
myeloproliferative neoplasm transformation myelofibrosis risk score DIPSS
ELN 2021 hydroxyurea resistance criteria polycythemia vera ruxolitinib second line 2024 guidelines
What to Do Next: Step-by-Step Clinical Management Plan
1. RISK STRATIFICATION (Do This First)
- Age ≥ 60 (55 years - borderline, but functional high-risk features dominate)
- Splenomegaly - present
- Persistent leukocytosis (WBC 13,200 on current CBC - still above normal)
- Tear-drop cells on peripheral smear - a warning sign of marrow fibrosis
- Macrocytosis (MCV 123 fL) - hydroxyurea effect, expected
2. BONE MARROW BIOPSY - THIS IS NOW MANDATORY
- Tear-drop cells (dacrocytes)
- Splenomegaly
- Persistent leukocytosis
- Thrombocytosis (platelets 4.5 lakh)
- 10 years of PV
- Bone marrow aspirate and trephine biopsy with reticulin and trichrome staining (grading fibrosis MF-0 to MF-3)
- Bone marrow cytogenetics
- Next-generation sequencing (NGS) / molecular panel - look for ASXL1, EZH2, SRSF2, IDH1/IDH2 mutations (these are "high-molecular-risk" mutations that worsen prognosis and influence transplant decisions)
3. ASSESS HYDROXYUREA RESPONSE CAREFULLY
- Need for phlebotomy to keep hematocrit <45% despite ≥2 g/day HU for ≥3 months
- Uncontrolled myeloproliferation (WBC >10,000 or platelets >400,000) on ≥2 g/day HU
- Failure to reduce massive splenomegaly by >50%
- Intolerance (Grade 3-4 non-hematologic toxicity, cytopenias at lowest dose, leg ulcers, skin cancers)
4. NEXT CBC AND MONITORING SCHEDULE
| Test | Timing |
|---|---|
| Full CBC with differential | Every 4 weeks while dose-adjusting |
| Peripheral smear review | At each clinic visit - watch for blasts |
| LFTs, uric acid, renal function | Monthly (hydroxyurea monitoring) |
| Serum erythropoietin level | If not previously checked |
| LDH | Now and serially - rising LDH suggests progression |
5. CONSIDER HYDROXYUREA DOSE ADJUSTMENT OR SWITCH
- Option A: Increase HU to 1,500 mg/day - feasible if no cytopenias (Hb 13.2 is acceptable, platelets 4.5 lakh is adequate headroom). Watch for dropping Hb below 10 g/dL, platelets below 1 lakh, or neutrophils below 1,000 - these are HU intolerance thresholds.
- Option B: Switch to Ruxolitinib (JAK1/2 inhibitor, 10 mg twice daily) - indicated if: (a) HU resistance confirmed, OR (b) symptomatic splenomegaly persists, OR (c) bone marrow confirms MF-2/MF-3 fibrosis. Harrison's 22E states: "Symptomatic splenomegaly can be treated with either ruxolitinib or pegylated IFN-α... ruxolitinib and pegylated IFN-α target the involved HSCs in PV and are not mutagenic; hydroxyurea does not target the involved HSCs in PV and is mutagenic." - Harrison's 22E, p. 864
- Option C: Ropeginterferon alfa-2b - if patient is younger, wants molecular remission, and splenomegaly is not massive. Less suited for post-PV MF evolution.
6. EVALUATE FOR POST-PV MYELOFIBROSIS FORMALLY
- Prior diagnosis of PV per WHO criteria ✅ (JAK2+, documented)
- Bone marrow fibrosis grade 2-3 (MF-2/MF-3) - pending biopsy
- Plus at least 2 of:
- Anemia OR sustained loss of requirement for phlebotomy/cytoreduction
- Leukoerythroblastic picture on blood smear
- Increasing splenomegaly (>5 cm increase, or new palpable splenomegaly)
- Development of ≥1 constitutional symptom (>10% weight loss in 6 months, night sweats, unexplained fever >37.5°C)
7. IF POST-PV MF IS CONFIRMED - DIPSS RISK SCORE AND TRANSPLANT EVALUATION
- Age > 65
- Constitutional symptoms
- Hemoglobin < 10 g/dL
- WBC > 25,000
- Circulating blasts ≥ 1%
- Platelet count < 100,000
- Red cell transfusion dependence
- Unfavorable cytogenetics
8. RUXOLITINIB FOR POST-PV MF SYMPTOMS
- Ruxolitinib (dose based on platelet count: platelets 4.5 lakh → start 20 mg twice daily) is first-line for intermediate-to-high risk post-PV MF per current guidelines
- Fedratinib 400 mg daily is an alternative JAK2 inhibitor if ruxolitinib fails or is not tolerated
9. THROMBOSIS PROPHYLAXIS - CONTINUE ASPIRIN
10. WATCH FOR BLAST TRANSFORMATION
- Any blast ≥ 1% on peripheral smear should prompt urgent bone marrow re-evaluation
- Accelerated phase = 10-19% blasts; Blast phase (AML) = ≥ 20% blasts
- This is a 10-20% lifetime risk in PV/post-PV MF patients
Summary Action Checklist (Prioritized)
| Priority | Action |
|---|---|
| Immediate | Bone marrow biopsy (aspirate + trephine, reticulin stain, cytogenetics, NGS panel) |
| Immediate | LDH, uric acid, serum EPO, peripheral smear review |
| This week | Consider increasing Hydroxyurea to 1,500 mg/day if no cytopenias |
| 4 weeks | Repeat CBC - if WBC > 10,000 persists at 1,500 mg/day, formally meeting HU resistance |
| After biopsy result | If MF-2/MF-3: Switch to or add Ruxolitinib, refer to BMT center |
| After biopsy result | If MF-0/MF-1: Continue HU optimization, increase surveillance |
| Ongoing | Continue Aspirin 150 mg, manage CV risk factors, phlebotomy if Hct > 45% |
| Ongoing | Monitor for blasts on every smear |